Meditorha.com | مدیتورها

مقاله شماره ۳۴

#Internal_medicine
#Diabete
#Cardiology
عنوان:

2019 ADA and EASD Guidelines for the Management of Hyperglycemia in Type 2 Diabetes

مجله:
Diabetes Care

نوع مطالعه:
Original Research

تاریخ انتشار:
October 15, 2019

سایتیشن:
Buse et al.

چکیده:
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

https://doi.org/10.2337/dci19-0066

توضیحات مهم:

✔ The ADA and EASD have updated their guidelines for the management of hyperglycemia in type 2 diabetes to include the use of GLP-1 receptor agonists or SGLT2 inhibitors in high-risk patients.
✔ The update also includes the consideration of GLP-1 receptor agonist use in those diabetic patients without cardiovascular disease and the use of SGLT2 inhibitors in type 2 diabetes patients with heart failure and chronic kidney disease.


🔎 @Meditorha

American Diabetes Association

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA)…

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperg

www.tgoop.com/meditorha/47

957 viewsDec 28, 2019 at 09:31

مقاله شماره ۳۴

#Internal_medicine
#Diabete
#Cardiology
عنوان:

2019 ADA and EASD Guidelines for the Management of Hyperglycemia in Type 2 Diabetes

مجله:
Diabetes Care

نوع مطالعه:
Original Research

تاریخ انتشار:
October 15, 2019

سایتیشن:
Buse et al.

چکیده:
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

https://doi.org/10.2337/dci19-0066

توضیحات مهم:

✔ The ADA and EASD have updated their guidelines for the management of hyperglycemia in type 2 diabetes to include the use of GLP-1 receptor agonists or SGLT2 inhibitors in high-risk patients.
✔ The update also includes the consideration of GLP-1 receptor agonist use in those diabetic patients without cardiovascular disease and the use of SGLT2 inhibitors in type 2 diabetes patients with heart failure and chronic kidney disease.


🔎 @Meditorha

BY Meditorha.com | مدیتورها